Maxwell Biosciences Raises $20M to Fuel Next-Generation Anti-Infectives Mimicking Human Immune Defenses

Maxwell Biosciences, a trailblazer in next generation anti-infectives that mimic natural human antimicrobial peptides, is thrilled to announce a pivotal funding milestone. The company has successfully raised $20,000,000 to expedite its transition from advanced preclinical studies to early-stage human trials. This crucial capital infusion will bolster Maxwell’s groundbreaking CLAROMER™ brand drug discovery platform—a proprietary system engineered to develop low molecular weight drug candidates capable of neutralizing formidable pathogens including SARS-CoV-2, HSV-1, and a broad spectrum of bacterial and fungal threats. Building on a robust history of over $35 million in non-dilutive grants and awards from global government entities, Maxwell Biosciences has already received strong validation for its science and technology from prestigious institutions. Studies conducted in US government-funded labs have confirmed the direct virucidal actions of its lead candidate against critical viruses, while independent research at Texas A&M and Baylor College of Medicine has demonstrated compelling tissue-safe toxicology profiles and breakthrough fungicidal actions in preclinical models. With these promising results in hand, the recent funding round is set to further refine and expand the company’s multi-asset, multi-target strategy in developing therapies that mirror the body’s own natural defenses. The newly secured funds will be strategically deployed to enhance advanced preclinical studies, fortify safety profiles, and ultimately catalyze the progression into human clinical trials. As Maxwell Biosciences continues to partner with leading pharmaceutical giants, this infusion of capital not only reinforces the company’s commitment to combating current and emerging infectious diseases but also underscores its mission to transform global healthcare through innovative, nature-inspired therapeutics.